Q-omics provides the consensus-scored PRR15 profile across patient tissues and cancer cell-line models. PRR15 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PRR15 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PRR15 RNA expression shows 17,767 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where PRR15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR15 survival associations across molecular data types. PRR15 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR15 RNA expression–survival associations across cancer types. High PRR15 expression shows unfavorable associations in LUAD, ACC and LGG, but favorable associations in THCA, UCEC and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PRR15 RNA expression.
This table summarizes PRR15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRR15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR15 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in THCA, BRCA and UCEC. The KIRC box plot shows higher PRR15 RNA expression in normal versus tumor tissue (log2 FC = −4.050, t-test p < 0.001).
This table shows molecular features associated with PRR15 in patient tissues and cancer cell lines. In patient samples, PRR15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
